Sort   by:  
 Page size 
UnknownAlterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Not available
S-EPMC6366295 | biostudies-literature
UnknownT-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.
Not available
S-EPMC5477923 | biostudies-literature
UnknownManagement of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Not available
S-EPMC6481621 | biostudies-literature
UnknownEfficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Not available
S-EPMC5791828 | biostudies-literature
UnknownEfficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
Not available
S-EPMC5559888 | biostudies-literature
UnknownRandomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.
Not available
S-EPMC3700777 | biostudies-literature
UnknownModulation of CTLA-4 and GITR for cancer immunotherapy.
Not available
S-EPMC4060248 | biostudies-literature
UnknownNivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Not available
S-EPMC5744258 | biostudies-literature
UnknownIntratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.
Not available
S-EPMC5316835 | biostudies-literature
UnknownPD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
Not available
S-EPMC5873884 | biostudies-literature
Sort   by:  
 Page size